Regenerative medicine startup to begin enrollment in phase 2 heart failure trial
Posted By Brandon Glenn On March 15, 2012 @ 9:28 am In MedCity News eNewsletter,Pharma,SYN,Top Story | No Comments
[1]Regenerative medicine startup Juventas Therapeutics [2] is planning to begin enrollment in a phase 2 heart failure clinical trial next quarter.
The Cleveland-based company’s technology, JVS-100 [3], works by recruiting stem cells from the bone marrow to create new blood vessels and prevent ongoing cell death at the site of a patient’s injury.
During the trial, Juventas will deliver its therapeutic via catheters from BioCardia, according to a statement [4] from California-based BioCardia.
In January, Juventas touted the 12-month results of its phase 1 heart failure trial [5]. At 12 months, heart failure patients treated with the company’s stem cell therapy showed “significant” improvements in two key measures: a six-minute distance-walking test and the Minnesota Living with Heart Failure Questionnaire [6], a patient self-assessment of how heart failure affects daily life.
In addition to the heart failure trial, Juventas has already begun enrollment in a phase 2a trial that will assess the safety and efficacy of JVS-100 in critical limb ischemia [7] patients.
Juventas was founded to commercialize technology developed by cardiologist Dr. Marc Penn [8], director of research at the Summa Cardiovascular Institute [9] in Akron, Ohio.
Article printed from MedCity News: http://medcitynews.com
URL to article: http://medcitynews.com/2012/03/regenerative-medicine-startup-to-begin-enrollment-in-phase-2-heart-failure-trial/
URLs in this post:
[1] Image: http://www.medcitynews.com/2011/10/your-cleveland-clinic-innovation-summit-preview-cardiology-edition/beating_heart/
[2] Juventas Therapeutics: http://www.medcitynews.com/tag/juventas-therapeutics/
[3] JVS-100: http://www.juventasinc.com/trials/index.html
[4] statement: http://www.businesswire.com/news/baybio/20120314006677/en
[5] heart failure trial: http://www.medcitynews.com/2012/01/stem-cell-therapy-company-juventas-encouraged-by-heart-failure-trial/
[6] Minnesota Living with Heart Failure Questionnaire: http://qol.thoracic.org/sections/instruments/ko/pages/mlwhfq.html
[7] critical limb ischemia: http://www.vdf.org/diseaseinfo/cli/
[8] Dr. Marc Penn: http://www.medcitynews.com/tag/marc-penn/
[9] Summa Cardiovascular Institute: http://www.medcitynews.com/2011/06/top-physician-entrepreneur-marc-penn-leaves-cleveland-clinic/
Click here to print.